6 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,
WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Voir le projet
13
Participants partenaires
TERMINÉ
European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)
Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet
34
Participants partenaires
TERMINÉ
A quantitative model of thrombosis in intracranial aneurysms (THROMBUS)
Date du début: 1 févr. 2011, Date de fin: 30 avr. 2014,
Rupture risk of intracranial aneurysms (IA) has been studied at length. However, very little is known about the healing mechanism, namely the formation of a clot inside the cavity after insertion of a stent. The multiscale interaction between biological and hemodynamic processes is the central ingredient of this proposal. The core of the project is to develop and validate a biological model of spo ...
Voir le projet
10
Participants partenaires
TERMINÉ
Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme (ALPHA-MAN)
Date du début: 1 oct. 2010, Date de fin: 31 mars 2014,
Alpha-Mannosidosis is a rare Lysosomal Storage Disorder with a worldwide incidence of about 1:500 000. This orphan and devastating disease is caused by the deficiency of the lysosomal alpha-mannosidase (LAMAN) which is responsible for the intralysosomal degradation of mannosyl linked oligosaccharides. To date no causative treatment for alpha-Mannosidosis is available and since most of the children ...
Voir le projet
12
Participants partenaires
TERMINÉ
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,
"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Voir le projet
12
Participants partenaires
TERMINÉ
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)
Date du début: 1 févr. 2009, Date de fin: 31 mars 2012,
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet